The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Abdomen-pelvis CT is the nation’s highest-volume CT category
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Subscribe To Our Newsletter & Stay Updated
